Hereditary Colon Cancer

Sign Up for Free Access to the
Latest Clinical Updates in Your Specialty!

Receive conference highlights, journal articles, and online medical education activities straight to your inbox.

Never Miss an Update

12 mins

Durvalumab for the Treatment of Advanced Biliary Tract Cancer test

Allan A Lima Pereira, Gabriel Lenz, Tiago Biachi de Castria

Despite being considered a rare type of malignancy, constituting only 3% of all gastrointestinal cancers, the incidence of biliary tract cancers (BTCs) has been increasing worldwide in recent years, with about 20,000 new cases annually only in the USA.1–3 These cancers arise from the biliary epithelium of the small ducts in the periphery of the liver […]

touchREVIEWS in Oncology & Haematology. 2025;21(1):Online ahead of journal publication

Durvalumab for the Treatment of Advanced Biliary Tract Cancer test

Allan A Lima Pereira, Gabriel Lenz, Tiago Biachi de Castria

touchREVIEWS in Oncology & Haematology. 2025;21(1):Online ahead of journal publication

Gastrointestinal Cancers

< 1 min

Hereditary Colon Cancer

Robin B Mendelsohn, Arnold J Markowitz

Published Online: Jun 15th 2012 European Gastroenterology & Hepatology Review, 2011;7(4):251–6

Quick Links:

Select a Section…

1. Abstract

2. Article

3. Further Resources

4. Related Content

Abstract

Overview

Colorectal cancer (CRC) remains one of the most common cancers in the world, and approximately 5–10 % of cases can be attributed to hereditary syndromes, including familial adenomatous polyposis, Lynch syndrome, MYH-associated polyposis, the hamartomatous syndromes, and their variants. Extensive research has identified the genes associated with many of these syndromes. Screening and management of patients with these conditions differs from that of the general population, and genetic testing and counselling has become crucial in this process. In this review, we discuss the different hereditary polyposis syndromes and their genetics, and emphasise approaches to the screening and surveillance of patients in the hope of preventing the morbidity and mortality currently associated with CRC.

Article

click here to read more

Further Resources

12 mins

Durvalumab for the Treatment of Advanced Biliary Tract Cancer test

Allan A Lima Pereira, Gabriel Lenz, Tiago Biachi de Castria

touchREVIEWS in Oncology & Haematology. 2025;21(1):Online ahead of journal publication

Related Content in Gastrointestinal Cancers

Foreword - touchREVIEWS in Oncology & Haematology, Volume 20, Issue 2, 2024

It is with great pleasure that we present the latest edition of touchREVIEWS in Oncology & Haematology. This issue highlights the remarkable progress and innovation shaping the fields of oncology and haematology, featuring articles that delve into both emerging therapies ...

Advancements in Immune Checkpoint Inhibitors for Oesophageal Squamous Cell Carcinoma: Current Status and Future Perspectives

Anahat Kaur, Michael K Gibson

Oesophageal cancer is the eighth most commonly diagnosed cancer and is the sixth leading cause of cancer death worldwide.1,2 Worldwide, around 604,100 new instances of oesophageal cancer were recorded in 2020, leading to approximately 544,100 deaths. This translates to a standardized incidence rate ...

touchREVIEWS in Oncology & Haematology. 2024;20(2):34–38

Advances in Targeting KRAS G12C in Gastrointestinal Malignancies: Focus on KRAS G12C Inhibitors

Celine Hoyek, Angelo Pirozzi, Jeremy Jones

Rat sarcoma virus (RAS) proteins are a family of prototypical oncogenes frequently mutated in human cancers. Mutations in the RAS gene account for 19% of all pathogenic alterations and are the subject of extensive research in molecular and clinical oncology.1 The ...

touchREVIEWS in Oncology & Haematology. 2024;20(2):25–33

Trifluridine/Tipiracil and Bevacizumab in Adults with Refractory Metastatic Colorectal Cancer

Gabriel Valagni, Nkafu Bechem Ndemazie, Tiago Biachi de Castria

Trifluridine/tipiracil (FTD/TPI) is a novel oral formulation of two drugs with promising results in the treatment of metastatic colorectal cancer (mCRC).1 Trifluridine is a thymidine-based nucleoside analogue that, after intracellular phosphorylation, gets incorporated into DNA, causing DNA dysfunction.2 ...

touchREVIEWS in Oncology & Haematology. 2024;20(2):19–24

Foreword - touchREVIEWS in Oncology & Haematology, Volume 20, Issue 1, 2024

Axel S Merseburger

Welcome to the latest issue of touchREVIEWS in Oncology & Haematology. We are honoured to present a series of compelling articles that reflect cutting-edge developments and diverse perspectives in this ever-evolving field. This issue includes a series of editorials and ...

Long-term Survival in Patients with Advanced Hepatocellular Cancer with Dual Immunotherapy Agents: Tremelimumab Plus Durvalumab

Amit Mahipal, Kanchi Patell, Richard Kim

Hepatocellular carcinoma (HCC) is the seventh most frequently occurring cancer in the world and the second most common cause of cancer mortality.1 The incidence of HCC has been growing rapidly, with a 75% increase in newly diagnosed cases from 1990 to 2015.2 Approximately 90% ...

touchREVIEWS in Oncology & Haematology. 2024;20(1):2–4

Futibatinib for the Treatment of Previously Treated, Unresectable, Locally Advanced or Metastatic Intrahepatic Cholangiocarcinoma with Fibroblast Growth Factor Receptor 2 (FGFR2) Gene Fusions or Other Rearrangements

Valerie Crolley, John Bridgewater

Cholangiocarcinoma (CCA) is a cancer of the epithelial cells lining the biliary tree in the liver and can occur both inside the liver (intrahepatic CCA [iCCA]) and outside the liver (extrahepatic CCA, which includes both perihilar and distal cholangiocarcinoma) (Figure 1). ...

touchREVIEWS in Oncology & Haematology. 2024;20(1):12–19

Fruquintinib in Patients with Previously Treated Metastatic Colorectal Cancer

Tiago Biachi de Castria, Ruoyu Miao, Richard D Kim

Outcomes for patients with metastatic colorectal cancer have steadily improve due to discovery of new drugs as well as increasing number patients undergoing local therapies.1 Angiogenesis is of a paramount importance in this disease and since vascular endothelial growth factor (...

touchREVIEWS in Oncology & Haematology. 2024;20(1):20–24

Foreword - touchREVIEWS in Oncology & Haematology, Volume 19, Issue 2, 2023

In the latest edition of touchREVIEWS in Oncology & Haematology, we are pleased to present a collection of articles that delve into the latest research and advancements in the field. From innovative therapies and genetic treatments to analyses of digital ...

Zolbetuximab: An Investigational First-Line Treatment for CLDN18.2-positive, HER2-negative Gastric and Gastro-oesophageal Junction Cancer

Joud Al Karmi, Michael K Gibson

Gastric and gastro-oesophageal junction (GOJ) adenocarcinomas are highly aggressive tumours with an overall poor prognosis, which is primarily attributable to the late stage of diagnosis resulting from nonspecific symptoms.1,2 While curative surgical resection is recommended for early-stage cases,3 advanced disease ...

touchREVIEWS in Oncology & Haematology. 2023;19(2):16-21

Incorporation of Combination Immunotherapy into the Treatment Paradigms of Gastrointestinal Cancers

Jeremy D Kratz, Nataliya V Uboha

The field of immuno-oncology has provided novel therapeutic agents that have led to significant improvements in patient outcomes across many tumour types. There have also been great efforts to incorporate immunotherapy (IO) into the treatment paradigms of gastrointestinal (GI) cancers. ...

touchREVIEWS in Oncology & Haematology. 2023;19(2):22-28

Foreword - touchREVIEWS in Oncology & Haematology, Volume 19, Issue 1, 2023

Welcome to the latest edition of touchREVIEWS in Oncology & Haematology, which features some of the recent key developments in oncological and haematological disease. The journal opens with an expert interview with Linda Martin on a new fluorescent imaging agent ...

Latest articles videos and clinical updates - straight to your inbox

Log into your Touch Account

Earn and track your CME credits on the go, save articles for later, and follow the latest congress coverage.

Error:

Forgot Password?

Or log in with

By proceeding, you agree to our terms & conditions.

For information about how we
use your data, see our privacy policy.

Register now for FREE Access

Register for free to hear about the latest expert-led education, peer-reviewed articles, conference highlights, and innovative CME activities.

Already have an Account?

Sign up with an Email

Or use a Social Account.

Error:

By clicking sign up you agree to the website
terms & conditions and privacy policy.

This Functionality is for
Members Only

Explore the latest in medical education and stay current in your field. Create a free account to track your learning.

Sign Up for Free Access to the
Latest Clinical Updates in Your Specialty!

Conference Coverage

Learning Activities

Journals

Durvalumab for the Treatment of Advanced Biliary Tract Cancer test

Conference Coverage

Learning Activities

Journals

Durvalumab for the Treatment of Advanced Biliary Tract Cancer test

Hereditary Colon Cancer

Abstract

Overview

Article

This Content is for
Members Only

Further Resources

1. Get Permission

2. Share This

Durvalumab for the Treatment of Advanced Biliary Tract Cancer test

Foreword - touchREVIEWS in Oncology & Haematology, Volume 20, Issue 2, 2024

Advancements in Immune Checkpoint Inhibitors for Oesophageal Squamous Cell Carcinoma: Current Status and Future Perspectives

Advances in Targeting KRAS G12C in Gastrointestinal Malignancies: Focus on KRAS G12C Inhibitors

Trifluridine/Tipiracil and Bevacizumab in Adults with Refractory Metastatic Colorectal Cancer

Foreword - touchREVIEWS in Oncology & Haematology, Volume 20, Issue 1, 2024

Long-term Survival in Patients with Advanced Hepatocellular Cancer with Dual Immunotherapy Agents: Tremelimumab Plus Durvalumab

Futibatinib for the Treatment of Previously Treated, Unresectable, Locally Advanced or Metastatic Intrahepatic Cholangiocarcinoma with Fibroblast Growth Factor Receptor 2 (FGFR2) Gene Fusions or Other Rearrangements

Fruquintinib in Patients with Previously Treated Metastatic Colorectal Cancer

Foreword - touchREVIEWS in Oncology & Haematology, Volume 19, Issue 2, 2023

Zolbetuximab: An Investigational First-Line Treatment for CLDN18.2-positive, HER2-negative Gastric and Gastro-oesophageal Junction Cancer

Incorporation of Combination Immunotherapy into the Treatment Paradigms of Gastrointestinal Cancers

Foreword - touchREVIEWS in Oncology & Haematology, Volume 19, Issue 1, 2023

Latest articles videos and clinical updates - straight to your inbox

Connect With Us

Useful Links

In Partnership With

Specialities

Sign Up for Free Access to the Latest Clinical Updates in Your Specialty!

Conference Coverage

Learning Activities

Journals

Trending Topic

Connect With Us:

Hereditary Colon Cancer

Abstract

Overview

Article

This Content is forMembers Only

Further Resources

1. Get Permission

2. Share This

Latest articles videos and clinical updates - straight to your inbox

Log into your Touch Account

Register now for FREE Access

Sign up with an Email

This Functionality is forMembers Only

Sign Up for Free Access to the
Latest Clinical Updates in Your Specialty!

This Content is for
Members Only

This Functionality is for
Members Only